



EP PerMed

European Partnership
for **Personalised Medicine**

European **P**artnership for **P**ersonalised **M**edicine

EP PerMed Joint Transnational Call, **JTC2026, Info day**

16 December 2025, online

Monika Frenzel, ANR, France, EP PerMed WP2 lead



**Co-funded by
the European Union**

EP PerMed has received funding from the European Union's Horizon Europe research and innovation program under grant agreement No **101137129**.

*The vision of the European Partnership for Personalised Medicine is to improve health outcomes within sustainable healthcare systems **through research, development, innovation and implementation of personalised medicine approaches** for the benefit of patients, citizens, and society.*

EP PerMed: **Setting & Budget**



Strategic Research and Innovation Agenda, **SRIA**

All European Partnerships develop a **SRIA**, which

- 🎯 identifies & elaborates of Research & Innovation priority areas, incl. activities to foster the development and implementation for coordinated actions
- 🎯 It is the **blueprint** for EP PerMed activities
- 🎯 It supports a wide range of stakeholders & experts to further **develop programs, activities, and research** to enable Personalised Medicine, Care and Prevention.
- 🎯 Additionally two SRIA **updates** are foreseen (**2027** and 2030)




EP PerMed **PM SRIA**
(April, 2023)



Have a look!

EP PerMed: Calls

support different steps for PM
in research, innovation and
implementation



EP PerMed
European Partnership
for Personalised Medicine

Joint Transnational Calls,
JTCs

Networking Calls, **NSC**

**Research, Innovation &
Technology Calls, RITCs**

"Fast Track" Calls

"Venture Creator" Calls

"Twinning Calls"

"Education Calls"

Research, Innovation & Technology Call, RITC2026:
Launched on 01 October
<https://www.eppermed.eu/funding-projects/calls/ritc2026/>

Fast Track 2026: Lunched on 2 December
<https://www.eppermed.eu/funding-projects/calls/fast-track-call/fast-track-validation-programme-2026/>

Twinning Call 2026: Matchmaking has started
<https://www.eppermed.eu/funding-projects/calls/twinning-call-2026/>

Thank You

General questions about EP PerMed: eppermed@dlr.de

Social Media: <https://www.linkedin.com/company/ep-permed/>

Website: www.eppermed.eu

Newsletter : <https://www.eppermed.eu/news-events/newsletter/>

- *EP PerMed Database, status: over 38 consortia with ~750 partners and more than 800 publications*
- *also Partner, Background, Calls, Events, News, PM Resources etc.*



**Co-funded by
the European Union**



EP PerMed
European Partnership
for **Personalised Medicine**



EP PerMed
European Partnership
for **Personalised Medicine**

Presentation of the JTC2026

CARMEN 2026



EP PerMed

European Partnership
for **Personalised Medicine**

EP PerMed JTC2026 « CARMEN2026 » Information Day

Joint Transnational Call (JTC) 2026 – CARMEN2026
Personalised Medicine for CARdiovascular,
MEtabolic, and kidNey diseases (CARMEN2026)

December 16th, 2025

Mylène Vaillancourt, Mérick Machouri, Monika Frenzel, ANR

Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases, "CARMEN2026"



38 funding
organisation

27 countries:

AU, BE, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE,
IL, IS, IT, LT, LU, LV, NL, NO, PL, PT, RO, SE,
SK, TR, ZA


9 regions:

BE (Wallonia-Brussels and Flanders),
IT (Lombardy and Tuscany),
PT (Azores and Centro region),
ES (Andalusia, Catalonia and Navarre)

38 M€
Commitment
of funders

Joint Call Secretariat (JCS):
The French National Research Agency (ANR)

Monika Frenzel
EPPerMed@agencerecherche.fr



Information about the JTC2026



EP PerMed website:

<https://www.eppermed.eu/funding-projects/calls/jtc2026/>

➤ **Call documents**

- **Electronic submission tool:** <https://ptoutline.eu/app/EPPERMED2026>
- **Partnering tool:** <https://www.b2match.com/e/eppermed-partnering>
- **Information about the Joint Call Secretariat (JCS) and the involved funders**
- **Short summary of the JTC2026**
- **General (eligibility) conditions for application**

Call Documents

Call Text (PDF)

Guidelines for Applicants (PDF)

Pre-proposal Form (DOCX)

Information about the JTC2026



Cooperation with Xjenza Malta

For the JTC2026, EP PerMed is cooperating with the Maltese funding agency Xjenza Malta. Through the Access2Partnerships (A2P) Scheme, Malta-based researchers can participate in the EP PerMed Call as partners on own funds and may be eligible for up to **€300,000 per project** to support their involvement in a successfully selected proposal, subject to a successful national application to Xjenza Malta.

Applicants need to submit a short administrative form to Xjenza Malta at least **15 working days before the pre-proposal submission deadline**.

[More information can be found here.](#)

Cooperation with Breakthrough T1D – CARMEN2026

In the framework of the Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (CARMEN2026), Breakthrough T1D offers the opportunity for researchers based anywhere in the world to participate as self-funded partners in successfully selected proposals with a clear focus on Type 1 Diabetes (T1D).

Researchers interested in linking their participation to Breakthrough T1D are required to **contact Breakthrough T1D at least 15 working days before the JTC pre-proposal deadline** (email to churtadodelpozo@breakthrough1d.org) to discuss scientific alignment and procedural requirements. Any potential involvement or support from Breakthrough T1D is subject to a separate internal review and approval process and is not automatically guaranteed through participation in the JTC.

Joint Transnational Call for Proposals (2026) for
**Personalised Medicine for CARDiovascular,
MEtabolic, and kidNey diseases (CARMEN2026)**

(EP PerMed Grant 101137129)

Call Text

Important Deadlines

Submission of pre-proposals: 10 February 2026 at 14:00 (CET)

Submission of invited full proposals: 09 June 2026 at 14:00 (CEST)

Link to the electronic proposal submission tool:

<https://ptoutline.eu/app/eppermed2026>

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

French National Research Agency (ANR)

86 rue Regnault, 75013 Paris, FRANCE

Monika Frenzel

Tel.: +33 1 73 54 83 32

Email: EPPERMed@agencerecherche.fr




**Co-funded by
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Rationale and Scope of the call

Rationale of the call

“Personalised Medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.”



Rationale of the call

- **Amongst the Top 10 causes of death:** Cardiovascular, metabolic and kidney diseases.
- **Billions of people affected – High economic burden for healthcare systems.**
- Many risk factors are already known but **still difficult to predict disease progression and efficacy of treatment in individual cases.**
- **Adverse events and treatment failures limit the effectiveness of conventional therapies →** Genetic variations, environmental factors, individual social / lifestyle characteristics.
- **Urgent need for Personalised Medicine strategies** to enable earlier identification of at-risk individuals, improve targeted prevention, and develop innovative therapies.

Scope of the call

Aims of the call

- To fund projects **in human health on innovative Personalised Medicine strategies for patients with cardiovascular, metabolic or kidney diseases.**
- Research projects **may focus on a single disease or explore these conditions in combination.**

Scope of the call

Aims of the call

Proposals should address one or more of the following aspects

- Development and validation of **innovative personalised therapeutic approaches** for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or *in silico* models).
- Identification and validation of molecular markers/signatures or cutting-edge technologies to **monitor treatment response** in patients with cardiovascular, metabolic or kidney diseases **in order to tailor treatment pathways**. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
- Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies **for early disease risk prediction and prevention of disease worsening or comorbidities** in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.

Scope of the call

Applicants are encouraged to combine the following aspects in their research proposal:

- 1. Multi-omics data** such as genomics, epigenomics, metagenomics, transcriptomics, proteomics and metabolomics data in relation to treatment outcomes. These data may be obtained from health data platforms or infrastructures, including population-level health databases.
- 2. Cutting-edge technologies** such as AI/ML algorithms, next-generation imaging technologies, digital health tools, etc. to enhance early diagnosis, monitor treatment response, optimise therapy effectiveness or dosage, and detect or prevent comorbidities and treatment-related side effects in patients.
- 3. Information regarding patient** medication, dose or compliance, medication efficacy, adverse effects, patient reported outcomes or patient preferences.
- 4. Additional factors** such as sex/gender dimension, age, environmental and social background, lifestyle, or nutritional status.

Scope of the call

Mandatory:

- Research projects **must focus on cardiovascular, metabolic or kidney diseases as the primary cause of illness.**
- Proposals **must be interdisciplinary** and clearly **demonstrate the potential impact on disease outcome and prevention through Personalised Medicine**, as well as **the added value of the transnational collaboration.**
- Required to include a **dedicated work package focussing on the question of the translation or implementation of the research outcomes into clinical practice** (see call text pages 7-8).

Excluded/out of scope:

- Research focussing only on drug-induced cardiac, metabolic or kidney toxicity is out of scope.
- Larger clinical trials are beyond the scope. Proposed clinical studies must be feasible and capable of being completed within the timeframe and budget of this call.

Scope of the call

Welcome:

- To combine a personalised medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular, metabolic and kidney diseases.
- To focus on a single cardiovascular, metabolic, or kidney disease, individually, or explore these conditions in combination.
- Clinical studies (exploratory/ proof-of-concept/ early-stage or sub-studies) may be funded under this call.

Scope of the call

Recommended/strongly encouraged:

- To use already existing cohorts and -omics data and integrated digital health data platforms.
- To integrate sex and gender research and underrepresented populations (e.g. ethnic minorities), or underrepresented patient sub-groups, e.g. children or elderly. To integrate social and cultural features like different economic, educational backgrounds.
- To build cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
- Active involvement of patients, citizens, healthcare providers, pharmacists and health and social care service users to raise awareness, share knowledge, improve dialogue and facilitate implementation.

Financial support for organisations representing patients or citizens in this call:

Funding centrally provided by EP PerMed or national/regional funding organisations.

Questions ?

Joint Transnational Call for Proposals (2026) for
**Personalised Medicine for CARDiovascular,
MEtabolic, and kidNey diseases (CARMEN2026)**

(EP PerMed Grant 101137129)

Call Text

Important Deadlines

Submission of pre-proposals: 10 February 2026 at 14:00 (CET)

Submission of invited full proposals: 09 June 2026 at 14:00 (CEST)

Link to the electronic proposal submission tool:

<https://ptoutline.eu/app/eppermed2026>

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

French National Research Agency (ANR)

86 rue Regnault, 75013 Paris, FRANCE

Monika Frenzel

Tel.: +33 1 73 54 83 32

Email: EPPERMed@agencerecherche.fr



**Co-funded by
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Eligibility criteria

Eligibility criteria – First stage

- Minimum 3 eligible partners*
- Maximum 6 partners*
- Maximum 7 partners*, if the consortium includes a 3rd partner of the same country (including the partner on own funds)
(condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium)

Three different EU Member States or Associated Countries whose funding organisations participate in the call


No more than 2 partners per funding organisation, including patient/citizen representing organisations **

No more than 2 partners per country, including partners on own funds **

No more than 1 partner on own funds */**

* Patient/citizen representing organisation are not included in this count

** Depending on the number of partners in the consortia and the respective funder's regulation




Eligibility criteria

- The **project coordinator (i.e. the principal investigator and the applicant's organisation) must be eligible to be funded** by his/her regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.
- **Organisations representing patients or citizens:**
 - Can request funding to EP PerMed or national/regional organisations.
 - Must be eligible (if requesting funding) and follow the general eligibility rules (no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations).
- **Widening – Second stage**
 - In the full proposal phase, possibility to add one partner from an underrepresented funding organisation.

Eligibility criteria – Summary

Three different EU Member States or Associated Countries whose funding organisations participate in the call

Number of partners in the proposal*	Pre-proposal					Full proposal (only by inclusion of one underrepresented region/country)
	3	4	5	6	7	+1
Maximum number of partners on own funds**	0	1	1	1	1	1
Maximum number of partners per country***	1	2	2	2	3	3 (if the number of partners in the full proposal stage sums up to 7 or 8)



Funding recipients


- A. Academia** (research teams working in universities, other higher education institutions) **or research institutes;**
- B. Clinical/public health sector** (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;
- C. Private for-profit (industry) partners, e.g. SME** (small and medium-sized enterprises) **and private non-profit partners**, e.g. foundations, associations or non-governmental organisations.

Strongly encouraged: **To include partners from different categories (A, B and C).**


Strongly recommended: **To integrate at least one early-career researcher (ECR) as principal investigator** in a consortium (for definition, see Call Text Annex III).

Consortium composition - examples

Minimal consortium: Minimum of 3 eligible and funded partners from 3 countries



FO: Funding organisation



Minimal consortium with 1 partner on own funds

Countries: EU Member State or Associated Countries*, whose funding organisations participate in the call (see list in the call text).


Partners: Each of these project partners must be eligible and request funding from their respective funding organisation. **No more than 1 partner on own funds is allowed** in consortia with at least 3 partners eligible for funding (and funded).

To note: the eligibility criteria may vary between funding organisation (Please check Annex III of the Guidelines for Applicants and get in contact with the respective funding organisation by using the “contact list” in the call text).


* Indications for Associated Countries and Third Countries to Horizon Europe: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratome_en.pdf

Consortium (Pre-proposal):

Example - Maximum 6 partners



FO: Funding organisation




Max. number of partners can be 6.

Patient/citizen representing organisations are not included in this calculation and can be added as additional partners in the pre-proposal or full proposal stage.


Max. 2 project partners per consortium can request funding from the same funding organisation, including patient/citizen organisations. For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one.

Consortium (Pre-proposal):

Example - Maximum 7 partners



FO: Funding organisation



Max. number of partners can be 7 if the consortium includes a 3rd partner of the same country

(**condition:** funding requested from at least 2 different funders of the respective country; applies to only one country per consortium)

...including the partner on own funds

To be considered

- If the **only role of an organisation (centre) is to provide patient data or samples for the study**, they can be included e.g. via cooperation agreements or subcontracting but not as full partner.

Eligibility criteria

Eligibility criteria vary with regards of the funding organisation

- Call text annex I or Guidelines for applicants annex I: Regional/National Contact Details
- Call text annex II: Indicative funding commitments of the participating funding organisations
- Guidelines for applicants Annex II: Guidelines for patient organisations or citizen organisations
- Guidelines for applicants Annex III: Information for applicants concerning regional/national eligibility criteria

Partnering tool

<https://www.b2match.com/e/eppermed-partnering>


The specific partnering for the JTC2026 within EP PerMed's partnering platform is now open.

From one call to the other: Personal profiles (*not*: cooperation offers) are preserved.

New registrations are / creation of new profiles is of course welcome.

For researchers that have entered new cooperation offers for the JTC2026 before December 15, please re-check indications, as questions have slightly changed.

For any questions about the EP PerMed partnering platform, please contact eppermed@dlr.de.



The screenshot displays the EP PerMed partnering platform interface. At the top, the EP PerMed logo is visible, along with the text "European Partnership for Personalised Medicine". Below this, a user profile for Monika Frenzel is shown, including a "Go to my profile" button and a "Share on LinkedIn" button. A "SUPPORT CONTACT INFORMATION" section provides an email address: eppermed@dlr.de. A "Participate" button is located at the bottom of the profile section.

The main form area is titled "Opportunity type: JTC 2026". It contains a text input field for a short title, a "Short description" field, and a "Full description" field with a rich text editor. A "Next Step" button is visible between the short and full description fields. A "Show on the organisation page" toggle switch is located at the bottom right of the form.

Opportunity type: JTC 2026

Please enter a short title for what you would like to offer in terms of cooperation opportunity, e.g. : "AI expert"; "transcriptomics expert"; "consortium looking for health economics expert."*

Short description*

Write a short version of full description below that will be visible in the list of cooperation offers. 140

Full description*

Please describe your potential contribution to an EP PerMed Proposal. In addition, please describe what you are looking for: A cooperation partner with a specific expertise? A consortium that might be interested in your expertise? Something else? This full description will be visible on the cooperation offers page

Show on the organisation page

The cooperation offer will also be visible on your organisation page under the Partnering tab.

You are not participating yet.

If you would like to participate in the partnering, you can see the options by clicking on the "Participate" button.

Participate

Questions ?

Joint Transnational Call for Proposals (2026) for
**Personalised Medicine for CARDiovascular,
MEtabolic, and kidNey diseases (CARMEN2026)**

(EP PerMed Grant 101137129)

Call Text

Important Deadlines

Submission of pre-proposals: 10 February 2026 at 14:00 (CET)

Submission of invited full proposals: 09 June 2026 at 14:00 (CEST)

Link to the electronic proposal submission tool:

<https://ptoutline.eu/app/eppermed2026>

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

French National Research Agency (ANR)

86 rue Regnault, 75013 Paris, FRANCE

Monika Frenzel

Tel.: +33 1 73 54 83 32

Email: EPPERMed@agencerecherche.fr



**Co-funded by
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Evaluation criteria and proposal submission

Evaluation criteria

- 1) **Excellence**
- 2) **Impact**
- 3) **Quality and efficiency of the implementation**

Scoring system:

- | | |
|----------------------|---|
| 0: Failure. | The proposal fails to address the criterion or cannot be assessed due to missing or incomplete information. |
| 1: Poor. | The criterion is inadequately addressed, or there are serious inherent weaknesses. |
| 2: Fair. | The proposal broadly addresses the criterion, but there are significant weaknesses. |
| 3: Good. | The proposal addresses the criterion well, but a number of shortcomings are present. |
| 4: Very Good. | The proposal addresses the criterion very well, but a small number of shortcomings are present. |
| 5: Excellent. | The proposal successfully addresses all relevant aspects of the criterion. Any shortcomings are minor. |

Please read carefully the Evaluation Criteria as well as the Aim and Expected Results, Outcome and Impacts sections.



PDF dossier

The pre- and full proposal templates, provided in word format and allowing applicants to present mainly the description of the planned work.

PT-OUTLINE

The electronic submission tool to provide particularly individual partner information and financial plans.



Both PT-Outline & the PDF dossier are time consuming!

Both parts should be completed jointly by all applying consortium partners and need to be started in due time.

PT-Outline - electronic submission tool



EPPERMED2026-001

Overview

[General Information](#)
[Checklist for the coordinator](#)
[Project Coordinator](#)
[Project Partner](#)
[Project description](#)
[Final Check and Submission](#)

proposals

submitted (1)

EPPERMED2026-001

in process (0)

Here you are able to add new proposals if necessary.

[create new](#)

Call details

Call acronym
EPPERMED2026

Call deadline
10-02-2026 14:00 CET

[EP PerMed JCS2026](#)

[The French National Research Agency \(ANR\)](#)

[Monika Frenzel](#)

EPPERMed@agencerecherche.fr

Overview

EP PerMed Joint Transnational Call 2026 "CARMEN2026"

The pre-proposal consists of two parts: The electronic form in this submission tool and a pdf document generated using the pre-proposal application form. Both parts contain important, non-redundant information and must be prepared jointly by the project consortium. It is crucial that the information given in both parts is consistent.

Some national or regional funding organisations require additional documents, see below.

Call Documents

The latest versions of the following call documents are available on the [EP PerMed Website](#):

- Call Text
- Guidelines for Applicants
- Pre-proposal application form

The full proposal application form will be made available in the second phase to consortia invited to submit a full proposal.

Additional regional/national documents (available for download on the EP PerMed website):

Some national or regional funding organisations require additional documents or require a parallel application process. If applicable, please download the respective additional regional/national documents from the [EP PerMed Website](#) and provide them to the respective funding organisations. Applicants are strongly advised to contact their relevant funding organisation prior to submission; please note that this step might be mandatory for some regions/countries. Please follow the specific indications described on the EP PerMed Website and in the Guidelines for Applicants.

Technical aspects

Please remember to save your data frequently using the "save" button at the bottom of each page, as entered data will be lost after two hours of inactivity. The proposal can be saved anytime and edited at a later stage until the final submission.

The proposal is stored password-protected. Connection to the server is SSL-encoded and data safety and protection of confidence are warranted.

Application Procedure

- 1 - Choose the proposal you are working on from the left side of the form.
- 2 - Enter all relevant information in the electronic forms for the coordinator and all project partners. Add as many partners as needed by clicking the button at the top of the project partner form.
- 3 - Upload the filled-in pre-proposal application form as a single pdf file under „project description“. Make sure that everything is consistent with the information entered into the electronic forms. Annexes have to be uploaded separately of the pre-proposal application form.
- 4 - Check the entries in the electronic forms. Under "Final check and submission", the system will show if all fields were filled in correctly. Here, you can also download a document containing all your entries.
- 5 - When all mandatory fields are filled in and the pre-proposal form as well as annexes are uploaded, the application can be submitted by clicking the "submit now" button. After this step, NO FURTHER CHANGES can be made.

PT-Outline

EPPERMED2026-001

[Overview](#)
[General Information](#)
[Checklist for the coordinator](#)
[Project Coordinator](#)
[Project Partner](#)
[Project description](#)
[Final Check and Submission](#)

EPPERMED2026-001

[Overview](#)
[General Information](#)
[Checklist for the coordinator](#)
[Project Coordinator](#)
[Project Partner](#)
[Project description](#)
[Final Check and Submission](#)

I confirm that all the points listed above were taken into account when preparing the pre-proposal. *

☒ yes

Submission of the same research proposal to other calls

Submission of the same research project to other calls: *

Is this submitted proposal subject to another ongoing evaluation process?

☐ Yes

☒ No

If yes, please specify

Was a similar proposal submitted before to the EP PerMed or ERA PerMed funding programme? *

This information is collected for statistical purposes only.

☒ The application is a new proposal

☐ A similar application was previously submitted to an EP PerMed or ERA PerMed Call

Save

General Information

All fields marked with * are mandatory for completing this form.

Project title (long title) *

Project acronym *

(max. 15 characters)
characters left: 16

Project duration (months) *

maximum 36 months

Total Budget (requested + in-kind) for the project

Sum for coordinator and all partners.

Will be calculated by the system, see "final check and submission" and downloadable document, please double-check.

Requested Budget for the project

Sum for coordinator and all partners.

Will be calculated by the system, see "final check and submission" and downloadable document, please double-check.

Keywords *

(from 5 up to 7)

Scientific Abstract *

(Do not exceed 2.000 characters including spaces. Please give a comprehensive and readable summary of the most important aims and methods of the project. The abstract given here should be identical to the one in the pre-proposal application form.)
characters left: 2000

PT-Outline

EPPERMED2026-001

Overview
General Information
Checklist for the coordinator
Project Coordinator
Project Partner
Project description
Final Check and Submission

Deleting this form.

Project coordinator

Gender *

Please choose...

Academic Title

First name *

Last name *

eMail *

Phone number *

Telephone DIN International (+1346 351 67055-794)

Principal Investigator

Please indicate the career stage *

Please choose...

PI role within the organisation *

Please choose...

Is this PI an Early Career Researcher (ECR)? *

For EP PerMeds definition of ECR, please consult Annex III of the call text.

☐ Yes

EPPERMED2026-001

Overview
General Information
Checklist for the coordinator
Project Coordinator
Project Partner
Project description
Final Check and Submission

Formbar

teambar

Delete form

Delete form

add project partner

Project Partner 2

All fields marked with * are mandatory for completing this form.

Project partner

Please note that the coordinator is not counted as partner here. A consortium consists of the coordinator plus partner 1, partner 2 etc.

Gender *

Please choose...

Academic Title

First name *

Last name *

eMail *

Phone number *

Telephone DIN International (+1346 351 67055-794)

Principal Investigator (PI)

Please indicate the career stage *

Please choose...

PI role within the organisation *

Please choose...

Is this PI an Early Career Researcher (ECR)? *

For EP PerMeds definition of ECR, please consult Annex III of the call text.

☐ Yes



EP PerMed
European Partnership
for **Personalised Medicine**

PT-Outline

EPPERMED2026-001

- Overview
- General Information
- Checklist for the coordinator
- Project Coordinator
- Project Partner
- Project description**
- Final Check and Submission

EPPERMED2026-001

- Overview
- General Information
- Checklist for the coordinator
- Project Coordinator
- Project Partner
- Project description
- Final Check and Submission**

Project description

Document upload

Please upload the pre-proposal application (see field "project description"), as one single pdf file not exceeding 8 MB. If applicable, please upload the patient/citizen involvement plan (Annex 6) and other annexes as separate pdf file (see below).

If applicable, you can upload additional documents (annexes) at this stage (see below).

Project description ^{*}

Duly filled in pre-proposal application form.

[eppermed2026-001_pre_proposal.pdf](#)

Browse... No file selected.

Letter of commitment for a project partner participating on own funds

Mandatory in full proposal stage if a partner wants to participate on own funds (no funding organisation selected). Single pdf file, max. 5 MB.

[eppermed2026-001_annex_4.pdf](#)

Browse... No file selected.

Supporting letters or endorsement letters

Single pdf file, max. 5 MB.

[eppermed2026-001_annex_5.docx](#)

Browse... No file selected.

Patient/Citizen involvement plan

Mandatory, if a patient organisation or citizen organisation applies for financial support from EP PerMed. Single pdf file, max. 5 MB.

[eppermed2026-001_annex_6.pdf](#)

Browse... No file selected.

Save

Final Check and Submission

! Proposal can not be modified anymore

 [download datasheet](#)

Uploaded files:

[eppermed2026-001_annex_4.pdf](#)
[eppermed2026-001_annex_5.docx](#)
[eppermed2026-001_annex_6.pdf](#)
[eppermed2026-001_full_proposal.pdf](#)
[eppermed2026-001_pre_proposal.pdf](#)

The "download datasheet preview" function allows you to download a pdf file containing all the information entered into the electronic forms. As this is part of your pre-proposal application, it is highly recommended to download and archive this file.

Binding Submission

- The pre-proposal can only be submitted after filling in all required fields in all sections.
- Please check your submission and click "Verify Submission".
- Then, please finalise your submission by clicking "submit now".
- **After finally submitting your proposal you cannot make any further changes.**

Project participants	Total funding volume	REQUESTED FUNDING
Mamteam	7€	7€
PapaBär	14€	14€
teambar	21€	21€
Overall	42€	42€

Verify Submission



EP PerMed
European Partnership
for **Personalised Medicine**

After finally submitting
your proposal you cannot
make any further changes.

Eligible annexes in the pre- and full proposal stage

There will be the possibility to add the following annexes

- **Annex 1** – Ethical self-assessment (**Mandatory**), at **full proposal stage** – template is provided as annex to the full proposal form, to be uploaded as separate file on PT-Outline;
- **Annex 2** – Description of the clinical research/study (if any), at **full proposal stage** – template is provided as annex to the **full proposal form**, to be uploaded as separate file on PT-Outline;
- **Annex 3** – Description of Animal Research Projects (if any), at full-proposal stage – template is provided as annex to the **full proposal** form, to be uploaded as separate file on PT-Outline;
- **Annex 4** – Letter of commitment for a project partner participating on own funds (if any; free format, at every stage; mandatory in the **full proposal stage**), to be uploaded as separate file on PT-Outline;
- **Annex 5** – Supporting letters (**at every stage**) or endorsement letters (**at every stage**) in free format (if any), to be uploaded as separate file on PT-Outline;
- **Annex 6** – Patient/Citizen involvement plan **Mandatory**, if a patient organisation or citizen organisation applies for financial support from EP PerMed – template is provided as annex to the pre- and full proposal forms, to be uploaded as separate file on PT-Outline.

Timeline of the call

25 November, 2025	Publication of the call
10 February, 2026 (14:00, CET)	Deadline for pre-proposal submission
Expected around 05 May, 2026	Communication of the results of the pre-proposal assessment and invitation to the full proposal stage
09 June, 2026 (14:00, CEST)	Deadline for full proposal submission
Mid/end of August 2026	Rebuttal stage
Expected for October 2026	Communication of the funding decisions to the applicants
End of 2026, beginning of 2027	Expected project start (according to regional/national funding regulations)

To conclude – to contact?

Read carefully the call text and the relevant central and regional/national eligibility and budgetary criteria before starting your proposal in order to check if **you as partner and the consortium as a whole** fulfil the call's formal requirements.

Clearly outline the **PERSONALISED MEDICINE** perspective in your research proposals.

To contact:

Recommended: Contact your respective funding agency prior to submitting the application.

Contact the Joint Call Secretariat for general questions.

Alternative other open calls being close to the topic of the CARMEN2026 call but NOT linked to EP PerMed:

PREVENT-OO: UNDERSTANDING AND PREVENTING OVERWEIGHT AND OBESITY - MECHANISMS OF THEIR ONSET AND PROGRESSION, NEGLECTED DETERMINANTS AND NOVEL STRATEGIES FOR CRITICAL TRANSITIONAL PERIODS IN LIFE

Aim of the call

*Project proposals should address multidisciplinary research. The applications must cover **only one** of the two following topics and address at least one of the two specified subtopics (subtopic 1a and/or 1b for topic 1 and subtopic 2a and/or 2b for topic 2); both topics and subtopics are of equal relevance for this call.*

The aim of this call is to support research that:

1. Improves the understanding of the causes for obesity, overweight and its complications by using a mechanistic approach.

And more specifically:

PREVENT-OO



Open Call

"Understanding and Preventing Overweight and Obesity"

#PreventOO_E4H



TRIALS4HEALTH: "MULTI-COUNTRY INVESTIGATOR-INITIATED CLINICAL TRIALS IN CARDIOVASCULAR, AUTOIMMUNE AND METABOLIC DISEASES"

Aims of the call

The aims of the call are:

- to support randomised interventional multi-country Investigator-Initiated Clinical Studies that are designed as **pragmatic comparative-effectiveness studies** and/or **drug repurposing studies**. The clinical trial design should be appropriate to answer the research question, and its selection shall be fully justified in the proposal. To exclude clinical studies with direct commercial purposes, the protocol and study design must be described in a very clear and transparent manner.
- to encourage and enable **transnational collaboration** between clinical/public health research teams (from hospital/ public health, healthcare settings and other healthcare organisations) that conduct multi-country IICS, either comparative-effectiveness or drug repurposing studies.

Trials4Health 2026



Now Open!!

"Multi-country Investigator-Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases"

#Trials4Health_E4H



Thank you

Questions?

**Joint Call Secretariat (JCS):
The French National Research Agency (ANR)**

Monika Frenzel
EPPerMed@agencerecherche.fr